Pfizer has initiated a Phase 3 trial for giroctocogene fitelparvovec (PF-07055480), a gene therapy targeting severe hemophilia A. This advancement reflects Pfizer's commitment to developing transformative treatments for rare diseases.
Following the transfer of the IND for giroctocogene fitelparvovec (formerly SB-525, now PF-07055480), we initiated our Phase 3 trial evaluating giroctocogene fitelparvovec gene therapy for the treatment of severe hemophilia A. The future is here. By digging deeper, asking bold questions, and leading scientific innovation, Pfizer Rare Disease is striving to go beyond disease control toward developing potentially transformative medicines and supporting healthy living at all stages of life.
Original title: “Rare Disease Drug Pipeline and Clinical Trials | Pfizer”